Tocagen

Tocagen receives FDA Breakthrough designation for glioma

Friday, February 24, 2017

Tocagen, a clinical-stage, cancer-selective gene therapy company, has announced the FDA granted Toca 511 & Toca FC Breakthrough Therapy designation for the treatment of patients with recurrent high grade glioma (HGG). Toca 511 & Toca FC is currently under evaluation in an international, randomized phase II/III clinical trial, which is designed to serve as a potential registrational study. The trial involves patients with first or second recurrence of glioblastoma or anaplastic astrocytoma who are undergoing resection. Enrollment in the phase II portion of the trial has completed and top-line results are anticipated in the first half of 2018.

[Read More]

Tocagen appoints Wood VP, regulatory affairs and quality assurance

Friday, February 19, 2016

Tocagen, a clinical-stage, cancer-selective gene therapy company, has named John Wood vice president of regulatory affairs and quality assurance. Wood holds more than 20 years of regulatory affairs experience focusing on first-in-class drugs for diseases with high unmet need. While at IDEC Pharmaceuticals, he played a leading role, in close collaboration with Genentech, in the first regulatory approval of RITUXAN for the treatment of immune system B-cell malignancies.

[Read More]